Concepedia

Dae Ho Lee

DH

Statistics

Publications

2

Citations

46

H-Index

2

Active since

2024

Affiliations

Aichi Cancer Center(Current)

Institut Gustave Roussy

Ulsan College

University of Ulsan

Asan Medical Center

Dae Ho Lee is an author at Aichi Cancer Center specializing in oncology, oncogenic ras mutations, and ras family oncogenes.

Publications per year

2024–2025

2

Publications

2

Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with <i>KRAS</i> G12C-mutant advanced NSCLC.

Timothy F. Burns, Konstantin H. Dragnev, Yutaka Fujiwara et al. · Journal of Clinical Oncology · 2024 · 35 citations

, , +16

Telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced <i>EGFR</i> -mutated (MT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase 1 study.

David Ross Camidge, Judith Raimbourg, Yun-Gyoo Lee et al. · Journal of Clinical Oncology · 2025 · 11 citations

, , +17

1–2 of 2